CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat
February 21, 2023 08:00 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration...
CinCor Pharma to be Acquired by AstraZeneca
January 09, 2023 02:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has...
Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update
November 04, 2022 08:00 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am...
CinCor Reports Third Quarter Financial Results and Provides Corporate Update
November 03, 2022 08:00 ET
|
CinCor Pharma Inc
Positive topline Phase 2 BrigHtn data demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Late-breaking...
CinCor Pharma to Present at the Jefferies Healthcare Conference
May 31, 2022 16:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York,...
CinCor Pharma to Present at Upcoming Investor Conferences
May 17, 2022 16:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place...
CinCor Reports First Quarter Financial Results and Provides Corporate Update
May 10, 2022 08:00 ET
|
CinCor Pharma Inc
Topline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for...
CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit
April 19, 2022 08:30 ET
|
CinCor Pharma Inc
WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in...
CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
March 22, 2022 08:19 ET
|
CinCor Pharma Inc
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled...
CinCor Pharma to be Added to Russell 2000® and Russell 3000® Indexes
March 17, 2022 08:00 ET
|
CinCor Pharma Inc
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the...